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Abstract
Background Despite improved preoperative imaging tech-
niques, patients with incurable or unresectable gastric cancer
are still subjected to non-therapeutic laparotomy. Diagnostic
laparoscopy (DL) has been advocated by some to be essential
in decision-making in gastric cancer. We aimed to identify and
synthesize findings on the value of DL for patients with gastric
cancer, in this era of improved preoperative imaging.
Methods Electronic literature searches were conducted
using Medline, EMBASE, and the Cochrane Central
Register of Controlled Trials from January 1, 1998 to
December 31, 2009. We calculated the change in man-
agement and avoidance of laparotomy based on the addi-
tion of DL and laparoscopic ultrasound (LUS). The
accuracy, agreement (kappa), sensitivity, and specificity of
DL in assessing tumor extent, nodal involvement, and the
presence of metastases with respect to the gold standard
(pathology) were also calculated.
Results Twenty-one articles were included. DL showed
moderate to substantial agreement with final pathology for
T stage, but only fair agreement for N stage. For M staging,
DL had an overall accuracy, sensitivity, and specificity
ranging from 85–98.9%, 64.3–94%, and 80–100%,
respectively. The use of DL altered treatment in 8.5–59.6%
of cases, avoiding laparotomy in 8.5–43.8% of cases. LUS
provided additional benefit in 5.8–7.2% of cases.
Conclusions Despite evolving preoperative imaging
techniques, diagnostic laparoscopy continues to be of
substantial value in staging patients with gastric cancer and
in avoiding unnecessary laparotomy. The current data
support DL for all patients with advanced gastric cancer.
Keywords Gastric cancer  Diagnostic laparoscopy 
Laparoscopic ultrasound  Cancer staging
Introduction
Despite developments in preoperative imaging, the sub-
optimal identification of advanced and incurable disease,
particularly carcinomatosis, results in high rates of
unnecessary laparotomies in patients with gastric cancer
[1–3]. Diagnostic laparoscopy has been suggested to
reduce these rates by identifying patients with unrecog-
nized incurable disease [4]. The addition of peritoneal
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lavage to diagnostic laparoscopy can identify patients with
free intraperitoneal cancer cells, the presence of which
connotes a poor prognosis [5]. Present guidelines recom-
mend diagnostic laparoscopy for advanced (T3 and T4)
gastric cancer without evidence of distant metastases on
preoperative imaging [4]. Despite this incorporation of
diagnostic laparoscopy in the gastric cancer treatment
algorithm [6, 7], its use remains haphazard. The uncertainty
of the continued utility of diagnostic laparoscopy in the era
of improved radiologic staging is likely the reason. Data
for Ontario show that only 5.1% of patients undergoing
curative resections had diagnostic laparoscopy [8]. In the
United States, based on data from the Surveillance, Epi-
demiology and End Results-Medicare (SEER-Medicare)
Linked Database, 8.3% of patients with gastric cancer
undergoing any surgery had diagnostic laparoscopy [3].
There is great variability in the literature regarding the
extent of evaluation and the organs to be inspected during
diagnostic laparoscopy. The Society of Gastrointestinal and
Endoscopic Surgeons (SAGES) guidelines reference the
technique proposed by D’Ugo et al. [5]. A pneumoperito-
neum is created and an angled laparoscope inserted via an
umbilical port. Cytology is performed either on aspirated
ascitic fluid or after instilling 200 ml of normal saline in the
absence of ascites [5]. Inspection of the peritoneal cavity
serves three purposes: (1) evaluation of tumor depth (T stage),
(2) identification of nodal disease (N stage), and (3) identi-
fication of gross peritoneal or liver metastases (M stage). The
anterior surface of the stomach and the perigastric, porta
hepatis, and gastrohepatic lymph nodes can be inspected and
biopsied by mobilizing the left lateral lobe of the liver. In
cases of posterior tumors, the lesser sac is opened and the
tumor visualized. Laparoscopic ultrasound has been recom-
mended to aid in the detection of deep liver metastases [4].
The goal of this systematic review is to provide a con-
temporary assessment of the value of diagnostic laparos-
copy in gastric cancer. This review will determine the
extent to which diagnostic laparoscopy benefits patients
with early gastric cancer (T1 and T2), and establish whe-
ther diagnostic laparoscopy is necessary in the era of
improved imaging technologies. In addition, the impact of
diagnostic laparoscopy on changing the management of
gastric cancer patients and avoiding unnecessary laparot-
omy will be assessed. Finally, the role and value of lapa-
roscopic ultrasound will be assessed in the staging process.
Methods
Data sources
Electronic literature searches were conducted in Medline
and EMBASE from January 1, 1998 to December 31, 2009
according to the search algorithm presented in Electronic
Appendix A. Search terms included: [exp Stomach Cancer/
or (((gastric or stomach) adj1 cancer$) or ((gastric or
stomach) adj1 carcinoma) or ((gastric or stomach) adj1
adenocarcinoma) or ((gastric or stomach) adj1 neo-
plasm$)).mp.] and [Laparoscopy/or peritoneal lavage/or
laparoscopic surgery/or Laparotomy/] or [clinical trial/or
controlled clinical trial/or exp comparative study/or meta
analysis/or multicenter study/or exp practice guideline/or
randomized controlled trial/] not [review or case report/or
*gastrointestinal stromal tumor/or exp B cell lymphoma/
and ‘‘marginal zone’’.mp.]. A separate search of the
Cochrane Central Register of Controlled Trials
(1998–2009) was performed using the search term ‘‘gastric
cancer’’. Studies were limited to English language. No
attempt was made to locate unpublished material.
Study selection and review process
To be eligible, studies had to meet the following criteria:
(1) studies that provided data on the role of diagnostic
laparoscopy in changing management or avoiding lapa-
rotomy; (2) the correlation of laparoscopy with final
pathology with respect to tumor stage, nodal status, and
metastatic disease; and (3) a minimum of 30 human
patients with confirmed histology of gastric adenocarci-
noma. Studies were excluded according to the following
exclusion criteria: (1) reviews, meta-analyses, systematic
reviews, abstracts, editorials or letters, case reports, and
guidelines; (2) studies where gastric adenocarcinoma data
could not be extracted from pooled results; and (3) studies
using animal models. No age, gender, or staging restric-
tions were employed. All electronic search titles, selected
abstracts; and full-text articles were independently
reviewed by a minimum of two reviewers (NC, PL, and
LL). Reference lists from review papers and relevant arti-
cles were also examined for additional studies that met our
inclusion criteria. Disagreements on study inclusion/
exclusion were resolved with a consensus meeting.
Data extraction
A systematic approach to data extraction was used to
produce a descriptive summary of participants, interven-
tions, and study findings. The first reviewer (PL) inde-
pendently extracted the data and a second reviewer (RC)
checked the data extraction. No attempt was made to
contact authors for additional information.
Data analysis
Various definitions were found for the calculation of
accuracy, sensitivity, and specificity. Therefore, values
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were re-calculated from the original numbers provided in
each included publication when possible. Accuracy was
defined as follows: (number of true positives ? number of
true negatives)/(number of true positives ? false posi-
tives ? true negatives ? false negatives) 9 100. Sensi-
tivity was calculated as follows: (number of true positives)/
(number of true positives ? number of false nega-
tives) 9 100. Specificity was defined as follows: (number
of true negatives)/(number of true negatives ? number of
false positives) 9 100. The kappa statistic with a 95%
confidence interval (CI) was calculated to obtain a quan-
titative measure of the magnitude of agreement between
diagnostic laparoscopy and histopathology. The following
interpretation of kappa was used: \0 = less than chance
agreement, 0.01–0.20 = slight agreement, 0.21–0.40 =
fair agreement, 0.41–0.60 = moderate agreement, 0.61–
0.80 = substantial agreement, and 0.81–0.99 = almost
perfect agreement [9]. Descriptive characteristics including
country of origin, study type, number of patients, patient
characteristics, location inspected, and staging classifica-
tion system used, as well as change in management and
avoidance of laparotomy, were also collected for each
included study.
Results
Search results
A total of 1129 abstracts/citations were identified from the
electronic and hand search for preliminary review. After
removal of duplicates and screening for relevant titles and
abstracts, a total of 435 articles were submitted for a full-
text review. Twenty-one articles [10–30] satisfied the
inclusion and exclusion criteria and were included in the
review (Fig. 1). The descriptive characteristics of each
included study are presented in Electronic Appendix B.
Study characteristics
Study design
Twelve studies were prospective [11, 13–16, 18, 19, 22–24,
29, 30] and nine were retrospective [10, 12, 17, 20, 21, 25–
28]. Pooled data, in nine studies that included either gastric
and esophagogastric cases [12, 17, 20, 23, 26, 27] or a
combination of upper gastrointestinal malignancies [10, 16,
29], required data extraction specific to gastric
adenocarcinoma.
Tumor stage
Four studies [11, 15, 19, 28] included patients with only
advanced tumor stage (T3 and T4). Early gastric cancers
(T1 and T2) were included in ten studies [14, 16–18, 20,
21, 23, 24, 26, 30]. The tumor stage was not defined in
seven studies [10, 12, 13, 22, 25, 27, 29]; however, all
cases included were considered curative based on preop-
erative imaging.
Preoperative staging
Preoperative staging investigations included endoscopy
with [10, 12, 15–18, 20, 21, 23, 26, 28] or without [14, 19,
22, 25] endoscopic ultrasound (EUS), barium studies [19],
abdominal ultrasound (AUS) [10, 12, 14–19, 25, 27–30],
computed tomography (CT) [10–12, 14–23, 25–28, 30],
magnetic resonance imaging (MRI) [16, 18, 23, 26, 30],
and positron emission tomography (PET) [18, 20]. CT was
the most consistently used preoperative staging investiga-
tion, being used in 18 studies.
Laparoscopic inspection
Diagnostic laparoscopy was performed in all studies. Five
studies failed to describe the procedure of laparoscopy [14,
20, 23, 26, 29]. Four studies made vague descriptions [11,
17–19]. Twelve studies specifically mentioned areas of
visualization but varied by inspection criteria: peritoneal
cavity [10, 12, 15, 16, 21, 22, 24, 25, 27, 28, 30], liver [10,
12, 13, 15, 16, 21, 24, 25, 27, 28, 30], omentum [10, 12, 21,
22, 25, 27], ligamentum teres [10], spleen [10], diaphragm
[12, 15, 22, 25, 30], stomach [12, 13, 15, 22, 24, 25, 27,
30], lymph nodes [12, 24, 25, 30], pelvis [12, 13, 22, 25,
30], pancreas [15], ovaries [16], and lesser sac [13, 16, 21,
22, 30].
Additional modalities
In addition to laparoscopic inspection, peritoneal lavage or
analysis of ascitic fluid was performed in nine studies [13,
Articles identified from search =1129 
Articles excluded based on title and abstract = 694 
Articles selected for full text review = 435 
Articles excluded = 414 
Articles included in this systematic review = 21
Fig. 1 Article selection flow
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17, 19, 20, 22–24, 28, 30]. Laparoscopic ultrasound, in
seven studies, was used as a supplemental method to detect
advanced local, nodal, and metastatic disease [15, 16, 18,
23, 26, 27, 29].
Study findings
Study findings are summarized in Tables 1, 2, 3, and 4. The
outcome measures of interest included are the accuracy,
sensitivity, and specificity of diagnostic laparoscopy in pre-
dicting T stage, N stage, and the presence of metastatic disease
missed by conventional preoperative staging tools. In addi-
tion, we examined the change in management and avoidance
of laparotomy with diagnostic laparoscopy and laparoscopic
ultrasound. The gold standard used was final pathology.
Preoperative T staging of gastric cancer by diagnostic
laparoscopy
Five studies assessed the use of diagnostic laparoscopy in
providing an accurate T stage. Three of the five studies
used laparoscopy alone [11, 14, 21], while two
incorporated laparoscopic ultrasound [16, 18]. Table 1
summarizes the results. The correlation between laparos-
copy and final pathology for T stage showed moderate to
substantial agreement based on kappa values ranging from
0.455 to 0.739.
Preoperative N staging of gastric cancer by diagnostic
laparoscopy
Three studies [14, 16, 18] assessed the use of diagnostic
laparoscopy in determining the N stage. As shown in
Table 2, the accuracy of diagnostic laparoscopy was
64.3%, 66.7%, and 98.9%. Two of the three studies [14,
18] calculated the correlation of diagnostic laparoscopy to
final pathology for N stage. Only fair agreement was shown
between the two (kappa = 0.324–0.340).
Preoperative M staging of gastric cancer by diagnostic
laparoscopy
Table 3 summarizes the results of the fifteen studies [10,
11, 14–16, 18, 19, 21–23, 25, 26, 28–30] where diagnostic
Table 1 Preoperative T staging of gastric cancer by diagnostic laparoscopy
Study Preoperative imaging used for T staging Accuracy Sensitivity Specificity Kappa (95% CI)
Blackshaw [11] CT T1/2 = 90%b T1/2 = 80%b T1/2 = 91%b 0.455 (0.303–0.608)a
T3 = 67%b T3 = 73%b T3 = 62%b
T4 = 77%b T4 = 58%b T4 = 93%b
Escrig Sos [14] CT OA = 84.4%a OA = 80.6%b OA = 100%b 0.624 (0.442–0.805)a
Hunerbein [16] CT/EUS/MRI OA = 97.7%a NR NR NR
Muntean [18] CT/EUS/MRI OA = 92.9%a OA = 50%a OA = 100%a 0.632 (0.140–1.124)a
Onate-Ocana [21] CT/EUS NR NR NR 0.739 (0.590–0.887)a
K kappa (agreement), CI confidence interval, OA overall, NR not reported/necessary information not provided, CT computed tomography, EUS
endoscopic ultrasound, MRI magnetic resonance imaging
a Calculated by literature review study team
b Calculations published in original manuscript
Table 2 Preoperative N staging of gastric cancer by diagnostic laparoscopy
Study Preoperative imaging used for N staging Accuracy (OA) Sensitivity (OA) Specificity (OA) Kappa (95% CI)
Escrig Sos [14] CT 66.7%a 60.8%a 93.8%b 0.324 (0.126–0.521)a
Hunerbein [16] AUS/CT/EUS/MRI 98.9%a NR NR NR
Muntean [18] AUS/CT/EUS/MRI/PET 64.3%b 54.5%b 100%a 0.340 (0.011–0.668)a
K kappa (agreement), CI confidence interval, OA overall, NR not reported/necessary information not provided, CT computed tomography, AUS
abdominal ultrasound, EUS endoscopic ultrasound, MRI magnetic resonance imaging, PET positron emission tomography
a Calculated by literature review study team
b Calculations published in original manuscript
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Table 3 Preoperative M staging of gastric cancer by diagnostic laparoscopy
Study Preoperative imaging
used for M staging
Accuracy Sensitivity Specificity
Arnold [10] AUS/CT Peritoneal = 95.9%a Peritoneal = 81.8%a Peritoneal = 100%a
Liver = 93.9%a Liver = 50%a Liver = 100%a
OA = 89.8%b OA = 64.3%b OA = 100%a
Blackshaw [11] CT Peritoneal = 85%b Peritoneal = 88%b Peritoneal = 83%b
Liver = 90%b Liver = 79%b Liver = 93%b
OA = 85%b OA = 94%b OA = 80%b
Escrig Sos [14] CT Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 91.1%a OA = 72.7%b OA = 97.1%b
Feussner [15] AUS/CT Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 95%a OA = NR OA = NR
Hunerbein [16] AUS/CT/MRI Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 92%b OA = 82%b OA = 100%b
Muntean [18] AUS/CT/MRI/PET Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 95.5%b OA = 89%b OA = 100%b
Nakagawa [19] AUS/CT Peritoneal = 90%a Peritoneal = 73.7%a Peritoneal = 100%a
Liver = NR Liver = NR Liver = NR
OA = NR OA = NR OA = NR
Onate-Ocana [21] CT Peritoneal = 98.1%a Peritoneal = 98.5%b Peritoneal = 97.6%b
Liver = NR Liver = NR Liver = NR
OA = NR OA = NR OA = NR
Osorio [22] CT/CXR Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 100%a OA = 100%a OA = 100%a
Power [23] CT/MRI Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 98.9%a OA = 94.7%a OA = 100%a
Roviaro [25] AUS/CT Peritoneal = 100%a Peritoneal = 100%a Peritoneal = 100%a
Liver = NR Liver = NR Liver = NR
OA = NR OA = NR OA = NR
Sarela [26] MDCT/MRI Peritoneal = NR Peritoneal = NR Peritoneal = NR
Liver = NR Liver = NR Liver = NR
OA = 91.3%a OA = 72.6%a OA = 100%a
Sotiropoulos [28] AUS/CT Peritoneal = 100%a Peritoneal = 100%a Peritoneal = 100%a
Liver = 93.3%a Liver = 0%a Liver = 100%a
OA = 91.1%a OA = 71.4%a OA = 100%a
Tang [29] AUS Peritoneal = 96.4%a Peritoneal = 87.5%a Peritoneal = 100%a
Liver = NR Liver = NR Liver = NR
OA = NR OA = NR OA = NR
Yano [30] AUS/CT/MRI Peritoneal = 93.4%a Peritoneal = 86.7%a Peritoneal = 100%a
Liver = 100%a Liver = 100%a Liver = 100%a
OA = 93.8%a OA = 88.2%a OA = 100%a
OA overall, NR not reported/necessary information not provided, AUS abdominal ultrasound, CXR chest X-ray, CT computed tomography, MDCT
multi-detector CT, MRI magnetic resonance imaging, PET positron emission tomography
a Calculated by literature review study team
b Calculations published in original manuscript
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laparoscopy was used to detect metastases. Eleven studies
evaluated the use of diagnostic laparoscopy in visually
detecting overall metastatic disease [10, 11, 14–16, 18, 22,
23, 26, 28, 30]. Four of these studies employed laparo-
scopic ultrasound [15, 16, 18, 23]. The accuracy of diag-
nostic laparoscopy ranged from 85–100%. The sensitivity
and specificity of the test ranged from 64.3–100% and
80–100%, respectively. For the four studies employing
laparoscopic ultrasound, the accuracy in detecting metas-
tases was 92–98.9%, compared to 85–100% in those where
laparoscopic ultrasound was not used.
Eight studies specifically evaluated the role of diag-
nostic laparoscopy in visually detecting peritoneal metas-
tases [10, 11, 19, 21, 25, 28–30]. The accuracy, sensitivity,
and specificity were 93.4–100%, 73.7–100%, and
83–100%, respectively. Four studies evaluated the benefit
of diagnostic laparoscopy in specifically detecting liver
metastases [10, 11, 28, 30]. None of these studies used
laparoscopic ultrasound. The accuracy, sensitivity, and
specificity were 90–100%, 50–100%, and 93–100%,
respectively.
Change in management and avoidance of laparotomy
Twenty studies reported the benefit of diagnostic lapa-
roscopy in changing management based on the detection
of advanced local disease or metastases [10–13, 15–30].
As shown in Table 4, diagnostic laparoscopy altered
management in 8.5–59.6% of cases, with 8.5–43.8% of
patients able to avoid laparotomy based on diagnostic
laparoscopy. Of the studies that specifically examined
change in management by stage, five studies demon-
strated that diagnostic laparoscopy changed management
in 25–54% of advanced (T3 and T4) cases [11, 15, 19, 23,
28], while one study [23] showed a 3.8% benefit in early
gastric cancer.
Table 4 Change in treatment strategy and avoidance of laparotomy based on diagnostic laparoscopy and laparoscopic ultrasound (LUS)
Study Complete preoperative work-up Change in
management
Avoidance of
laparotomy
Change added by
LUS
Change added by
PL
Arnold [10] Endoscopy/EUS/AUS/CT (NR) OA = 18.4%b OA = 18.4%b NA NA
Blackshaw [11] H-CT OA = 54%a OA = 34%a NA NA
de Graaf [12] Endoscopy/EUS/AUS/CT (NR) OA = 28%b NA NA NA
Deogracias [13] NR OA = 12.2%a OA = 12.2%a NA NR
Feussner [15] Endoscopy/EUS/AUS/H-CT OA = 40.5%a NA OA = 7.2%b NR
Hunerbein [16] EUS/AUS/H-CT/MRI OA = 34.4%a OA = 23.7%a NR NA
Kaiser [17] Endoscopy/EUS/AUS/CT (NR) OA = 25.5%a OA = 25.5%a NA NA
Muntean [18] EUS/AUS/CT (NR)/MRI/PET T1-3 = 33.3%a NA OA = 6.7%a NR
T4 = 66.7%a
OA = 37.8%b
Nakagawa [19] Endoscopy/barium meal/US/CT (NR) OA = 56%a OA = 22%b NA NA
Nath [20] EUS/CT (NR)/PET OA = 28.8%b OA = 28.8%b NA 7.9%
Onate-Ocana [21] Endoscopy/EUS/CT (NR) OA = 43%a OA = 31.1%b NA NA
Osorio [22] Endoscopy/CXR/CT (NR) OA = 20.6%a OA = 15.9%a NA NR
Power [23] EUS/CT (NR)/MRI T1-2 = 3.8%a OA = 19.1%b NR NR
T3-4 = 25%a
OA = 19.1%b
Ribeiro [24] NR OA = 16.3%b OA = 16.3%b NA NR
Roviaro [25] Endoscopy/US/CT (NR) OA = 8.5%b OA = 8.5%b NA NA
Sarela [26] EUS/MDCT/MRI OA = 39%a OA = 23%a NR NA
Smith [27] US/H-CT OA = 59.6%a OA = 28.9%a OA = 5.8% NA
Sotiropoulos [28] Endoscopy/EUS/AUS/CT (NR) OA = 31.1%a OA = 31.1%a NA NR
Tang [29] AUS OA = 25% OA = 25% NR NA
Yano [30] AUS/CT (NR)/MRI OA = 53.1%a OA = 43.8%b NA NR
LUS laparoscopic ultrasound, PL peritoneal lavage, AUS abdominal ultrasound, CXR chest X-ray, CT computed tomography, H-CT helical CT,
MDCT multi-detector CT, EUS endoscopic ultrasound, MRI magnetic resonance imaging, PET positron emission tomography, NA not appli-
cable, NR not recorded/necessary information not provided, OA overall
a Calculated by literature review study team
b Calculations published in original manuscript
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The benefit of laparoscopic ultrasound
Three studies [15, 18, 27] commented on the additional
effect of laparoscopic ultrasound on changing manage-
ment. Laparoscopic ultrasound altered management in an
additional 5.8–7.2% of cases.
Discussion
The use of diagnostic laparoscopy as an essential investi-
gation in gastric cancer is not universally established.
Current guidelines vary in their recommendations. SAGES
[4] guidelines recommend the use of diagnostic laparos-
copy in advanced (T3 and T4) cancers and are against its
use in early gastric cancer (T1 and T2) (Grade B recom-
mendation). Both the European Society for Medical
Oncology (ESMO) [31] and the National Comprehensive
Cancer Network (NCCN) [7] recommend the use of diag-
nostic laparoscopy in any patient thought to have resectable
disease (Grade B recommendation). SAGES [32] also
recommends that laparoscopic ultrasound be employed
when staging laparoscopy is undertaken. With such vari-
ability in guidelines and expert opinion, review of the most
recent data seems warranted. Additionally, with newer
preoperative imaging tools, such as multi-detector CT CT
(MDCT), PET, and MRI, some authors have questioned the
need for diagnostic laparoscopy [26].
Diagnostic laparoscopy for T staging
A recent systematic review suggested that EUS, MDCT,
and MRI were equivalent in establishing T stage in gas-
tric cancer, but recommended EUS as the most appro-
priate investigative modality due to the larger body of
supportive evidence [33]. Accuracy rates for EUS,
MDCT, and MRI were quoted as 65–92.1%, 77.1–88.9%,
and 71.4–82.6%, respectively [33]. Our review has shown
moderate to substantial agreement between laparoscopic
findings and final pathology, with accuracy rates of up to
97.7%. However, the clinical relevance only seems to lie
in distinguishing lesions deemed unresectable (T4) by
imaging modalities from resectable (T3) ones. The use of
laparoscopic ultrasound for this purpose is supported by
SAGES guidelines [32]. However, a recommendation
based on the included studies is not possible due to the
paucity of data.
In studies where both early and advanced gastric cancer
patients were included [14, 16, 18], better accuracy was
achieved when laparoscopic ultrasound was used [16, 18].
However, although laparoscopic ultrasound appeared to be
accurate in the staging of early gastric cancer, this did not
impact operative management.
Diagnostic laparoscopy in early gastric cancer
The likelihood of disseminated or unresectable disease
increases with T stage [34]. Consequently, the utility of
diagnostic laparoscopy in early gastric cancer management
is controversial. Our review identified only one trial [23]
that specifically examined the impact of diagnostic lapa-
roscopy on T1 and T2 cancers, showing change in man-
agement in only 3.8% of patients. In comparison, our
review found the most evidence to support diagnostic
laparoscopy for T3 and T4 cancers, where changes in
management occurred 31.1–66.7% of the time [10, 14, 17,
18, 22, 28]. Based on our findings, we would recommend
diagnostic laparoscopy for patients found to have T3 and
T4 cancers. Further studies need to be conducted on early
gastric cancer cases, and when all T stages are included in
an analysis, caution should be taken in interpreting the
results.
The presence of metastases precluding curative resec-
tion in early gastric cancer is rare [34]. Though there may
not be sufficient evidence to recommend diagnostic lapa-
roscopy in early gastric cancer, a subset of patients may
benefit—those who are misdiagnosed as having early
gastric cancer. Certain prognostic factors have been iden-
tified in this subset of patients and may be used selectively
to determine those who may benefit from diagnostic lapa-
roscopy. These factors include upper-third and middle-
third tumor localizations, a tumor size from 2 to 5 cm,
undifferentiated adenocarcinoma, Lauren’s diffuse type,
endolymphatic invasion, vascular invasion, and perineural
invasion [35].
Diagnostic laparoscopy for N staging
We are unable to provide recommendations on the value of
laparoscopy in nodal staging as our review is based on only
three studies. The literature shows that conventional
imaging tools lack sensitivity in identifying metastatic
lymph nodes. A recent systematic review has suggested
that neither AUS, EUS, MDCT, conventional MRI, nor
PET can reliably confirm or exclude the presence of lymph
node metastasis [2]. Further studies on the use of laparos-
copy and laparoscopic ultrasound for the evaluation of
nodal status would be beneficial.
Diagnostic laparoscopy for M staging
The current recommendations for preoperative staging of
gastric cancer include abdominal imaging with CT and
optional PET [7]. Based on a recent meta-analysis [36], the
accuracy of CT and PET in detecting overall metastatic
disease was lower than the accuracy we found in our
review of diagnostic laparoscopy (81.2% and 88.2%,
S44 P.-A. Leake et al.
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respectively, versus 89.8–100%). In our review, up to
59.6% of patients who had been previously staged as M0
by CT, PET, or MRI were found on diagnostic laparoscopy
to have incurable disease, supporting the additional benefits
conferred by diagnostic laparoscopy.
Laparoscopy appears to be superior to conventional
preoperative staging investigations in detecting peritoneal
carcinomatosis. The accuracy of identifying peritoneal
metastases by CT ranges from 30% [37] to 100% [38], with
a sensitivity as low as 28.8% [39]. The sensitivity of AUS
to detect peritoneal metastases is poor, reported as 9% [40].
PET scanning consistently shows low sensitivity in
detecting peritoneal metastases, with rates of 30% [41] and
35.3% [42].
Laparoscopy does not appear to provide additional
benefit over preoperative imaging for the detection of liver
metastases. Guidelines suggest the preoperative imaging
modality of choice to be CT [7]. However, studies show
high variability in its accuracy, sensitivity, and specificity
(60–100% [11, 38, 39, 41], 60–100% [11, 38, 39, 41], and
91.5–100% [11, 43], respectively). As a result, PET has
been advocated as an alternative superior modality [44],
although this acceptance is not universal [45]. The sensi-
tivity rate for diagnostic laparoscopy of 0–79% found in
our review is likely related to the ability of laparoscopy to
only visualize superficial liver lesions. Laparoscopic
ultrasound, in contrast, has the benefit of identifying deep
liver metastases [32]. We are unable to comment on its
benefit as an adjunct to diagnostic laparoscopy as its role
for the detection of liver metastases was not examined in
the included studies. The role of laparoscopic ultrasound in
the identification of liver metastases requires further eval-
uation, but currently is recommended for this purpose by
SAGES (Grade B—based on high-level, well-performed
studies with varying interpretations and conclusions by
expert panels) [32].
Change in management, avoidance of laparotomy,
and the benefit of laparoscopic ultrasound
Based on the studies included in this systematic review,
diagnostic laparoscopy changed the management of up to
59.6% (8.5–59.6%) of gastric cancer patients who were
initially deemed resectable by preoperative imaging. This
predominantly involved identifying patients who had
metastatic disease and who would not benefit from either
laparotomy or neoadjuvant therapy (including those who
may be accrued for ongoing trials). In addition, up to
43.8% of patients who were identified as incurable avoided
laparotomy altogether. This illustrates the resounding
benefit of diagnostic laparoscopy as a preoperative tool for
optimizing patient outcomes and preventing unnecessary
physical and psychological stresses through ineffective
procedures [46, 47]. The added value of laparoscopic
ultrasound in changing management appears to be minimal
based on the included studies. Although published data
suggest that through the identification of occult metastases
and involved lymph nodes, laparoscopic ultrasound
improves the sensitivity of diagnostic laparoscopy, making
it superior to conventional imaging [48], this was not
clearly borne out in our review due to the small number of
published studies.
Diagnostic laparoscopy in the era of improved
preoperative imaging
With reports of improved preoperative staging of gastric
cancer with advanced imaging technologies (MDCT,
MRI, PET) [38, 41], it has been predicted that diagnostic
laparoscopy would become obsolete. Our review does
not support this premise. The one study that specified
MDCT as a preoperative imaging tool [26] suggested
that laparoscopy may be omitted in advanced gastric
cancer patients with primary tumors not involving the
gastroesophageal junction or whole stomach and who
have no lymphadenopathy, as diagnostic laparoscopy did
not confer any further change in management in this
subset of patients. Although this subgroup was identified,
there was still an overall change in management in 39%
of the patients in that study based on the addition of
diagnostic laparoscopy and despite the use of MDCT
preoperatively. Three of twelve studies in which the type
of CT scan used for staging was not specified enrolled
patients during the 2000s when advanced CT technolo-
gies were likely used [18, 20, 23]. Again, diagnostic
laparoscopy resulted in management changes in
19.1–37.8% of these patients. The failure of identifica-
tion of peritoneal metastases by CT, despite the use of
16- or 64-detector row scanners [1], appears to be the
major contributing factor to the poor performance of CT.
MRI and PET fared no better, as the studies that
employed these modalities [16, 18, 20, 23, 26, 30] still
showed significant changes in management based on
diagnostic laparoscopy of 19.1–53.1%.
Conclusion
Laparoscopy shows reasonable correlation with final
pathology in identifying T stage, but there are insufficient
data to comment on the benefit of laparoscopy in identi-
fying lymph node involvement. Laparoscopy is additive to
conventional imaging in detecting overall metastatic dis-
ease and peritoneal carcinomatosis, and therefore laparos-
copy shows significant benefit in changing management
and avoiding unnecessary laparotomy in patients with
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gastric cancer. Laparoscopic ultrasound has minimal
additional value in this regard.
Despite evolving preoperative imaging techniques,
diagnostic laparoscopy appears to sustain substantial value
in the staging of patients with gastric cancer. The morbidity
and mortality of non-therapeutic laparotomy can be avoi-
ded through its use. Its benefit in advanced gastric cancer is
clear although the benefit of its use in early gastric cancer
is questionable. Laparoscopic ultrasound does not appear to
be an essential staging tool in gastric cancer.
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